Monoclonal Antibody Therapies for High Risk Neuroblastoma
Wayne L Furman Department of Oncology, St. Jude Children’s Research Hospital, Memphis, TN, USACorrespondence: Wayne L FurmanDepartment of Oncology, St. Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105, USATel +1-901-595-2403Fax +1– 901-521-9...
Saved in:
Main Author: | Furman WL |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/4d92fc6f80074bf6bbc35d6506e3485d |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy
by: Keyel ME, et al.
Published: (2018) -
A Novel pH-Sensitive Multifunctional DNA Nanomedicine: An Enhanced and Harmless GD2 Aptamer-Mediated Strategy for Guiding Neuroblastoma Antitumor Therapy
by: Zhang L, et al.
Published: (2021) -
Nanomicellar Lenalidomide–Fenretinide Combination Suppresses Tumor Growth in an MYCN Amplified Neuroblastoma Tumor
by: Orienti I, et al.
Published: (2020) -
Variable Expression of the Disialoganglioside GD2 in Breast Cancer Molecular Subtypes
by: Ramona Erber, et al.
Published: (2021) -
How Can We Engineer CAR T Cells to Overcome Resistance?
by: Glover M, et al.
Published: (2021)